(4) Policy Briefing: A New Agenda For CMS, The Biden White House, And A Democratic Congress The Certara Market Access Channel podcast

Kandungan disediakan oleh Certara Evidence & Access and Certara Evidence. Semua kandungan podcast termasuk episod, grafik dan perihalan podcast dimuat naik dan disediakan terus oleh Certara Evidence & Access and Certara Evidence atau rakan kongsi platform podcast mereka. Jika anda percaya seseorang menggunakan karya berhak cipta anda tanpa kebenaran anda, anda boleh mengikuti proses yang digariskan di sini https://ms.player.fm/legal.

The Certara Market Access Channel »
(4) Policy Briefing: A new agenda for CMS, the Biden White House, and a Democratic Congress

3+ y ago 20:34

Kongsi

MP3•Laman utama episod

We're finally back with a new season for the Radar Podcast, pharma's flagship intelligence briefing on all things market access, real-world evidence, and payer strategy. This program is brought to you by the experts in Certara's global Evidence & Access practice.

In this episode, we're discussing the Biden administration's policy positions, the fate of Trump-era CMS proposals, and what the new majority in the 117th Congress will mean for the biopharma industry.

Your host for this week is Max Goldstein, Director of Business Development, speaking to Ulrich Neumann, Senior Director, Access and Commercial Strategy. For any questions on the topics discussed today, please contact ulrich.neumann@certara.com or download our latest whitepapers here: https://www.certara.com/evidence-access/us-managed-markets/key-trends-us-specialty/

--- Send in a voice message: https://podcasters.spotify.com/pod/show/market-access/message

4 episod

#Science #Certara Evidence & Access #Certara Evidence